Loss of gene expression and splicing regulatory function are now widely accepted features of ALS with TDP-43 proteinopathy, but how the specific complement of TARDBP mRNA targets drives pathogenesis and phenotype remains unclear. Here, TARDBP is linked to amyotrophic lateral sclerosis.